Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Apalutamide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    45 result(s) found for: Apalutamide. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2018-000899-15 Sponsor Protocol Number: EORTC-1531-ROG Start Date*: 2019-12-03
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: Radiotherapy and 6-month androgen deprivation therapy with or without apalutamide in Intermediate and Limited High Risk Localized Prostate Cancer: a phase III study
    Medical condition: Intermediate and Limited High Risk Localized Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000735-32 Sponsor Protocol Number: 56021927PCR3002 Start Date*: 2015-09-21
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
    Medical condition: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) DE (Completed) ES (Ongoing) CZ (Trial now transitioned) PL (Completed) RO (Trial now transitioned) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002957-46 Sponsor Protocol Number: 56021927PCR3015 Start Date*: 2020-05-13
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Controlled, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with Hormone-Sensitive Pr...
    Medical condition: High risk recurrent prostate cancer previously treated with radical prostatectomy
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Trial now transitioned) CZ (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) PT (Trial now transitioned) BE (Trial now transitioned) SK (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001746-34 Sponsor Protocol Number: 56021927PCR3011 Start Date*: 2019-04-02
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy
    Medical condition: High-risk localized or locally advanced prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001700-29 Sponsor Protocol Number: TAPS01 Start Date*: 2018-04-05
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust & The University of Cambridge
    Full Title: Targeted drug intervention to inhibit cancer progression in men on active surveillance for prostate cancer. Therapeutics in Active Prostate cancer Surveillance (TAPS01)
    Medical condition: Prostate cancer, managed by active surveillance - low or intermediate risk according to NICE classification and an MRI score of ≥ 3 for lesion probability using PIRAD version 2 reporting criteria.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-000155-21 Sponsor Protocol Number: UC-0160/1702 Start Date*: 2019-07-23
    Sponsor Name:UNICANCER
    Full Title: An open label, randomized, phase III study, evaluating the efficacy of a Combination of Apalutamide with Radiotherapy and LHRH Agonist in high-risk postprostatectomy biochemically relapsed prostate...
    Medical condition: High-risk biochemically-relapsed prostate adenocarcinoma following radical prostatectomy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-004322-24 Sponsor Protocol Number: ARN-509-003 Start Date*: 2013-08-27
    Sponsor Name:Aragon Pharmaceuticals, Inc
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer
    Medical condition: Castration-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Trial now transitioned) FI (Completed) SE (Completed) NL (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) NO (Completed) DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned) HU (Completed) CZ (Trial now transitioned) SK (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004365-13 Sponsor Protocol Number: CTOR18001GZA Start Date*: 2019-02-04
    Sponsor Name:GZA vzw
    Full Title: A phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) with LHRH agonist or antagonist versus anti-adrogen therapy...
    Medical condition: Prostate cancer patients with biochemical progression after radical prostatectomy and planned for salvage radiotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003523-16 Sponsor Protocol Number: ARN-I-20-DEU-003-V01 Start Date*: 2021-12-29
    Sponsor Name:Universität des Saarlandes
    Full Title: A feasibility trial investigating inductive Apalutamide therapy combined with radical prostatectomy in patients with locally advanced T4 high risk prostate cancer
    Medical condition: patients with locally advanced T4 high risk prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001266-29 Sponsor Protocol Number: PC-ARN-IPC-2015-025 Start Date*: 2017-02-09
    Sponsor Name:Institut Paoli Calmettes
    Full Title: Active surveillance with or without a 6 months Apalutamide treatment in low risk prostate cancer: a phase II randomized multicenter trial
    Medical condition: Low risk localized prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007113 Cancer of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004329-10 Sponsor Protocol Number: UKM17_0018 Start Date*: 2020-07-09
    Sponsor Name:Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel
    Full Title: A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy
    Medical condition: High risk adenocarcinoma of the prostate after radical prostatectomy (RPE)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006674-22 Sponsor Protocol Number: 56021927PCR2046 Start Date*: 2022-12-12
    Sponsor Name:VÝCHODOSLOVENSKÝ ONKOLOGICKÝ ÚSTAV, a.s.
    Full Title: AD ASTRA (Androgen Deprivation with Apalutamide and STereotactic RAdiotherapy) Prospective institutional phase II study of efficacy and safety of androgen deprivation with apalutamide in high-risk ...
    Medical condition: Localized or a locally advanced high-risk prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002854-19 Sponsor Protocol Number: S58827 Start Date*: 2017-08-03
    Sponsor Name:UZ Leuven
    Full Title: Neoadjuvant degarelix +/- apalutamide (ARN-509) followed by radical prostatectomy for intermediate and high-risk prostate cancer: a randomized, placebo-controlled trial.
    Medical condition: Prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003141-28 Sponsor Protocol Number: CCR4500 Start Date*: 2017-04-04
    Sponsor Name:The Institute of Cancer Research
    Full Title: ACE: Proof of concept Phase I/II trial of the CXCR2 antagonist AZD5069, administered in combination with enzalutamide, in patients with metastatic castration resistant prostate cancer(mCRPC)
    Medical condition: Metastatic castration resistant prostate cancer
    Disease:
    Population Age: Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-001718-25 Sponsor Protocol Number: 56021927PCR3001 Start Date*: 2015-04-02
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemoth...
    Medical condition: Metastatic castration-resistant prostate cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Trial now transitioned) BE (Completed) DE (Trial now transitioned) IT (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000348-77 Sponsor Protocol Number: XL184-315 Start Date*: 2020-07-22
    Sponsor Name:Exelixis, Inc.
    Full Title: A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant ...
    Medical condition: Metastatic Castration-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed) GB (GB - no longer in EU/EEA) PT (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) AT (Completed) GR (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003007-38 Sponsor Protocol Number: 56021927PCR3003 Start Date*: 2016-01-11
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy
    Medical condition: High- or very-high risk, localized or locally advanced prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) DE (Ongoing) BE (Trial now transitioned) NL (Completed) PL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000082-41 Sponsor Protocol Number: 2021-0486 Start Date*: 2022-03-31
    Sponsor Name:Fundación para la Investigación en Urología
    Full Title: Impact of pitavastatin use in prostate cancer patients treated with new generation androgen therapy: multicenter clinical trial
    Medical condition: We propose a multicenter, prospective, randomized, single-blind clinical trial, without conflict of interest, to determine the clinical benefit of statins (Pitavastatin 2 mg) in prostate cancer pa...
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000290-24 Sponsor Protocol Number: I3Y-MC-JPCY Start Date*: 2020-08-17
    Sponsor Name:Eli Lilly and Company
    Full Title: CYCLONE 1: A Phase 2 Study of Abemaciclib in Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated with a Novel Hormonal Agent and Taxane-based Chemotherapy
    Medical condition: Metastatic Castration-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-000076-37 Sponsor Protocol Number: NL72585.091.20 Start Date*: 2023-03-30
    Sponsor Name:Radboud University Medical Center
    Full Title: Lutetium-177-PSMA in Oligo-metastatic Hormone Sensitive Prostate Cancer.
    Medical condition: Oligo-metastatic adenocarcinoma of the prostate.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CY (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 14:56:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA